

HE Dr Bahar Idriss Abu Garda
Minister of Health
Federal Ministry of Health
PO Box 303
Khartoum,
The Republic of Sudan

14 December 2016

Decision Letter: 2017 Renewal of Gavi vaccine and Health Systems Strengthening support

Your Excellency

I am writing in relation to Sudan's request for 2017 renewal of Gavi support to the Menengitis-A, Pneumococcal, Pentavalent and Rotavirus Vaccines, and the Health Systems Strengthening programme that was reviewed by Gavi High Level Review Panel on 5 to 7 of October 2016.

Following the recommendations made by the High Level Review Panel, I am pleased to inform you that Gavi has **approved** Sudan's request, subject to several conditions and requirements as specified in the Appendices to this letter. Please note that Sudan's request for IPV support was approved, but due to worldwide IPV supply constrains the relevant decision letter will be sent at a later date, once supply issues have been resolved.

Additionally, I am pleased to inform you that Sudan is eligible for a US\$1.584.000 performance payment based in the achievements of its Health Systems Strengthening programme in 2015. In order to proceed with the disbursement of the performance payment, Sudan is requested to submit a budget and workplan of how to utilize these funds to enhance immunisation programme outcomes **within 3 months** of receipt of this letter and incorporate the funds into the operational plan and budget for the next planning year. Any performance payments approved in 2016 that are not disbursed by the end of 2017 will be cancelled and removed from country commitments.

The Appendices include the following important information:

- Appendix A: Financial and Programatic information – Support for Menengitis-A Vaccine (Men-A)
- Appendix B: Financial and Programatic information – Support for Pneumococcal Vaccine (PCV)
- Appendix C: Financial and Programatic information – Support for Pentavalent Vaccine
- Appendix D: Financial and Programatic information – Support for Rotavirus Vaccine
- Appendix E: Financial and Programatic information – Support for Injection Safety Devices
- Appendix F: Financial and Programatic information – Health Systems Strengthening (HSS)
- Appendix G: Recommendations of the High Level Review Panel
- Appendix H: Final 2016 Joint Appraisal Report



Please do not hesitate to contact my colleague Mrs. Anne Cronin at acronin@gavi.org if you have any questions or concerns.

Yours sincerely

A handwritten signature in blue ink that reads "Hind Khatib-Othman". The signature is written in a cursive, flowing style.

Hind Khatib-Othman
Managing Director, Country Programmes

cc: The Minister of Finance
 The Director of Medical Services
 Director Planning Unit, MoH
 The EPI Manager
 WHO Country Representative
 UNICEF Country Representative
 Regional Working Group
 WHO HQ
 UNICEF Programme Division
 UNICEF Supply Division

Decision Letter
Sudan - Support for Meningitis A Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Republic of Sudan			
2. Grant number: 17-SDN-28a-X			
3. Date of Decision Letter: 14/12/2016			
4. Date of the Partnership Framework Agreement: 10/12/2013			
5. Programme title: New Vaccine Support (NVS) - Meningitis A Preventive Routine			
6. Vaccine type: Meningitis A			
7. Requested product presentation and formulation of vaccine: Meningococcal type A, 10 dose(s) per vial, LYOPHILISED			
8. Programme duration¹: 2016-2017			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2016	2017	Total²
Programme Budget (US\$)	700,500 ³	1,350,500	2,051,000
10. Vaccine introduction grant (in US\$): . Not applicable			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2016	2017	
Number of Meningitis A vaccines doses		2,651,500	
Annual Amounts (US\$)	US\$700,500 ⁵	US\$1,350,500	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable.			
14. Co-financing obligations: Reference code: 17-SDN-28a-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.			
Type of supplies to be purchased with Country funds in each year	2017		
Number of vaccine doses	319,500		
Number of AD syringes	193,700		
Number of re-constitution syringes	35,200		
Number of safety boxes	2,525		
Value of vaccine doses (US\$)	US\$156,432		
Total co-financing payments (US\$) (including freight)	US\$174,000		
15. Operational support for campaigns: Not applicable.			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

16. Additional reporting requirements: Not applicable	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable.	
18. Other conditions: Not applicable.	

Signed by,



On behalf of Gavi
 Hind Khatib-Othman
 Managing Director, Country Programmes
 14 December 2016

Decision Letter
Sudan - Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: the Republic of Sudan			
2. Grant number: 17-SDN-12c-X			
3. Date of Decision Letter: 14/12/2016			
4. Date of the Partnership Framework Agreement: 10/12/2013			
5. Programme title: New Vaccine Support (NVS) - Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID			
8. Programme duration⁶: 2013 -2017			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2013-2016	2017	Total⁷
Programme Budget (US\$)	76,134,741 ⁸	15,193,500	91,328,241
10. Vaccine introduction grant (in US\$): Not applicable.			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁹			
Type of supplies to be purchased with Gavi funds in each year	2013-2016	2017	
Number of Pneumococcal vaccines doses		4,027,900	
Annual Amounts (US\$)	US\$76,134,741 ¹⁰	US\$15,193,500	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable.			
14. Co-financing obligations: Reference code: 17-SDN-12c-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.			
Type of supplies to be purchased with Country funds in each year	2017		
Number of vaccine doses	503,600		
Number of AD syringes	527,600		
Number of safety boxes	5,825		
Value of vaccine doses (US\$)	US\$1,661,645		
Total co-financing payments (US\$) (including freight)	US\$1,767,500		

⁶ This is the entire duration of the Programme.

⁷ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁸ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁹ This is the amount that Gavi has approved.

¹⁰ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

15. Operational support for campaigns: Not applicable	
16. Additional reporting requirements: Not applicable	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2017
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable	
18. Other conditions: Not applicable.	

Signed by,



On behalf of Gavi
 Hind Khatib-Othman
 Managing Director, Country Programmes
 14 December 2016

Decision Letter
Sudan - Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Republic of Sudan			
2. Grant number: 17-SDN-04a-X			
3. Date of Decision Letter: 14/12/2016			
4. Date of the Partnership Framework Agreement: 10/12/2013			
5. Programme title: New Vaccine Support (NVS) - Pentavalent Routine			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 1 dose(s) per vial, LIQUID			
8. Programme duration¹¹: 2008-2017			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2008-2016	2017	Total¹²
Programme Budget (US\$)	88,079,215 ¹³	7,289,000	95,368,215
10. Vaccine introduction grant (in US\$): Not applicable.			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ¹⁴			
Type of supplies to be purchased with Gavi funds in each year	2008-2016	2017	
Number of Pentavalent vaccines doses		3,952,600	
Annual Amounts (US\$)	88,079,215 ¹⁵	7,289,000	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: No applicable.			
14. Co-financing obligations: Reference code: 17-SDN-04a-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.			
Type of supplies to be purchased with Country funds in each year	2017		
Number of vaccine doses	491,800		
Number of AD syringes	525,200		
Number of safety boxes	5,800		
Value of vaccine doses (US\$)	US\$872,844		
Total co-financing payments (US\$) (including freight)	US\$933,500		
15. Operational support for campaigns: Not applicable			

¹¹ This is the entire duration of the Programme.

¹² This is the total amount endorsed by Gavi for the entire duration of the Programme.

¹³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

¹⁴ This is the amount that Gavi has approved.

¹⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

16. Additional reporting requirements: Not applicable	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2017
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable.	
18. Other conditions: Not applicable.	

Signed by,



On behalf of Gavi
 Hind Khatib-Othman
 Managing Director, Country Programmes
 14 December 2016

**Decision Letter
Sudan - Support for Rotavirus Vaccine**

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Republic of Sudan			
2. Grant number: 17-SDN-13b-X			
3. Date of Decision Letter: 14/12/2016			
4. Date of the Partnership Framework Agreement: 10/12/2013			
5. Programme title: New Vaccine Support (NVS) - Rotavirus Routine			
6. Vaccine type: Rotavirus			
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule			
8. Programme duration¹⁶: 2011-2017			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2011-2016	2017	Total¹⁷
Programme Budget (US\$)	32,364,888 ¹⁸	3,275,000	35,639,888
10. Vaccine introduction grant (in US\$): Not applicable			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ¹⁹			
Type of supplies to be purchased with Gavi funds in each year	2011-2016	2017	
Number of Rotavirus vaccines doses		1,456,500	
Annual Amounts (US\$)	US\$32,364,888 ²⁰	US\$3,275,000	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable.			
14. Co-financing obligations: Reference code: 17-SDN-13b-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.			
Type of supplies to be purchased with Country funds in each year	2017		
Number of vaccine doses	190,500		
Value of vaccine doses (US\$)	US\$417,126		
Total co-financing payments (US\$) (including freight)	US\$428,500		
15. Operational support for campaigns: Not applicable			

¹⁶ This is the entire duration of the Programme.

¹⁷ This is the total amount endorsed by Gavi for the entire duration of the Programme.


¹⁸ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

¹⁹ This is the amount that Gavi has approved.

²⁰ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

16. Additional reporting requirements: Not applicable	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2017
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable.	
18. Other conditions: Not applicable	

Signed by,



On behalf of Gavi
 Hind Khatib-Othman
 Managing Director, Country Programmes
 14 December 2016

**Decision Letter
Sudan - Support for Injection safety devices**

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: the Republic of Sudan		
2. Grant number: 17-SDN-32a-X		
3. Date of Decision Letter: 14/12/2016		
4. Date of the Partnership Framework Agreement: 10/12/2013		
5. Programme title: Injection Safety Devices ²¹		
6. Programme duration²²: 2017		
7. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)		
	2017	Total²³
Programme Budget (US\$)	556,500	556,500
8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ²⁴		
TOTAL injection safety devices to be purchased with Gavi funds in each year		2017
Number of AD syringes		10,787,700
Number of re-constitution syringes		291,700
Number of safety boxes		121,925
Annual Amounts for injection safety devices for all Gavi vaccines (US\$)		US\$556,500
Injection safety devices to be purchased with Gavi funds in each year, <u>by type of support</u>		
New Vaccine Support (NVS), Pneumococcal (PCV13), 1 dose(s) per vial LIQUID,Routine		2017
Number of AD syringes		4,219,700
Number of safety boxes		46,425
Annual Amounts for injection safety devices for Vaccine (US\$)		US\$213,000
New Vaccine Support (NVS), DTP-HepB-Hib, 1 dose(s) per vial, LIQUID		2017
Number of AD syringes		4,221,200
Number of safety boxes		46,450
Annual Amounts for injection safety devices for Vaccine (US\$)		US\$213,000
New Vaccine Support (NVS), Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID,Routine²⁵		2017
Number of AD syringes		737,900

²¹ This does not include vaccines.

²² This is the entire duration of the Programme.

²³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

²⁴ This is the amount that Gavi has approved.

²⁵ Please note that Sudan's request for IPV support was approved, but due to worldwide IPV supply constrains the relevant decision letter for IPV doses will be sent at a later date, once supply issues have been resolved.

Number of safety boxes	8,125
Annual Amounts for injection safety devices for Vaccine (US\$)	US\$37,500
New Vaccine Support (NVS), Meningococcal type A, 10 dose(s) per vial, LYOPHILISED, Routine	
Number of AD syringes	1,608,900
Number of re-constitution syringes	291,700
Number of safety boxes	20,925
Annual Amounts for injection safety devices for Vaccine (US\$)	US\$93,000
9. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.	
10. Self-procurement: Not applicable.	
11. Co-financing obligations: Co-financing requirements are listed in the relevant vaccine Decision Letter.	

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
14 December 2016

Decision Letter
Sudan, Republic of Health Systems Strengthening Programme

This Decision Letter forms part of the PFA and together with the PFA sets out the Programme Terms of the Programme. Any term used in this Decision Letter but not defined shall have the meaning given to such term in the PFA.

1. Country: Republic of Sudan
2. Programme payment grant number: 1418-SDN-10a-Y Performance payment grant number: 16-SDN-10e-Y
3. Date of Decision Letter: 14/12/2016
4. Date of the Partnership Framework Agreement (the “PFA”): 10/12/2013
<p>5. Programme: Health Systems Strengthening (HSS)</p> <p>For further information about the Programme please refer to:</p> <ul style="list-style-type: none"> • Gavi HSS guidelines and HSS application form available by contacting your Gavi country manager; • Country's approved grant proposal together with any responses to the HSS independent review committee (IRC's) request for clarifications; • The workplan and budget document circulated by email describing the expected Programme Activities and Programme Budget as at the Date of the Decision Letter sent on 29 April 2014.
<p>6. Gavi performance based funding</p> <p>The Programme shall be subject to Gavi's performance-based funding (PBF). Under this, the HSS support will be split into two payments: the programmed payment (based on implementation of the Programme) and the performance payment (based on improvements in immunisation outcomes). This means that in the first year, Country will receive 100% of the year one annual amount, as an upfront payment. After year one, countries will receive 80% of the annual amount, based on implementation of the grant. Note that countries whose total grant budget would fall below US\$3 million are exempt from this 80% rule.</p> <p>Country will have the opportunity to receive payments beyond the programme budget amount, for exceptional performance. Such performance payments will be based on performance on immunisation outcome indicators. For any given year, the programmed payment and performance payment may total up to 150% of the country's year one annual amount (upfront investment).</p> <p><u>Performance payments for a given year will be made the following year, based on performance of the indicators listed and data verification.</u></p> <p>Gavi calculation of performance payments for 2015 achievements – TOTALS:</p> <p>Given that Country's DTP3 coverage was at or above 90% at baseline, which is defined as the year prior to the first year of HSS grant implementation, and based on WHO/UNICEF estimates, Country will be rewarded for sustaining high coverage with:</p> <ul style="list-style-type: none"> • 20% of annual country ceiling for maintaining DTP3 coverage at or above 90% and • 20% of annual country ceiling ensuring that 90% of districts have at or above 80% DTP3 coverage.

Countries with DTP3 coverage \geq 90% at baseline					TOTAL Performance payment to the country
Reported DTP3 coverage (WUENIC) at baseline	Eligibility for DTP3 performance payment	Amount of DTP3 performance payment (US\$)	Eligibility for geographic equity performance payment	Amount of geographic equity performance payment (US\$)	
93%	Eligible	1,584,000	Not eligible	0	1,584,000

Should Sudan wish to request the full details of the calculation method leading to the TOTAL amount of the performance payment, please contact your Gavi senior country manager Anne Cronin at acronin@gavi.org

7. Programme Duration: 2014 to 2018

8. Programme Budget: This is the amount of an estimated multi-year budget endorsed by Gavi under the Programme.

Note that with PBF, annual disbursements may be more or less than these endorsed amounts after the first year.

Programme Year	2014-2015	2016	2017	2018	Total
Programme Budget (US\$)	14,249,652	6,325,194	6,329,998	6,326,922	33,231,766
Performance payment (US\$)	1,584,000	1,584,000			

9. Annual Amounts: This is the estimated annual amount Gavi has approved to be disbursed under the Programme. The Country acknowledges that:

- (a) a proportion of the Annual Amount may be disbursed directly to an agreed implementing agency, such as WHO and UNICEF, rather than to the Country; and
- (b) each Annual Amount may be disbursed in a number of tranches at quarterly or six-monthly intervals.

Programme year	2014-2015	2016
Annual Amount (\$US)	14,249,652	6,325,194
Performance payment (\$US)	1,584,000	1,584,000

10. Outstanding comments/clarifications: Not applicable.

11. Documents to be delivered: Not applicable.

12. Other conditions: The following terms and conditions shall apply to the Programme.

Any requested adjustments to the Annual Amounts will be subject to Gavi approval. It is essential that Country's Health Sector Coordination Committee (or its equivalent) be involved with this process both in its technical process function and its support during implementation and monitoring of the Programme. Utilisation of Gavi support stated in this letter will be subject to performance monitoring.

If the bank account information most recently provided to Gavi has changed or changes prior to disbursement, the country will need to complete a bank account information form. Please contact gavihss@gavi.org for the form.

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

14 December 2016

The Panel, following its deliberations:

- Recommended to the CEO:

Programme	Recommendation	Period	Indicative amount to be paid by Gavi
NVS – PCV in existing presentation	Extension	2017	US\$ 15,193,500
NVS – Pentavalent in existing presentation	Extension	2017	US\$ 7,289,000
NVS – Rotavirus in existing presentation	Extension	2017	US\$ 3,275,000
NVS – IPV ²⁶ in existing presentation	Renewal	2017	US\$ 668,000
NVS -Yellow Fever in existing presentation	Extension (subject to availability of supply)	2017	US\$ 19,865,000
HSS – Core tranche	Renewal	2017	US\$ 6,325,194
HSS – Performance Payment	Approval	2016	US\$ 1,584,000

- Commended the country and the partners for the quality of the JA;
- Noted the ongoing work by World Bank on the Health Financing assessment on UHC and stressed the importance of making sure that immunization is prioritized as an essential component of universal health coverage;
- Noted the reliable gender disaggregated data and encouraged that focus should now be placed on gender related barriers, using data from health surveys and better understanding of gender disparities;
- Noted with concern the HR retention issue and EPI strengthening needs and stressed importance of embedding PEF support within EPI and also to advocate at a higher political level including at ICCs the importance of addressing this challenge through appropriate policy shifts;
- Emphasized the weaknesses around the ICC functioning and stressed the importance of ongoing work in Leadership Management and Coordination in strengthening ICC and its functioning and capacities.
- Stressed the importance of looking at expanded partners to give support to country to ensure financial management capacity and to address the findings identified in the Audit.
- Noted the following prioritised country needs, as identified in the Joint Appraisal:

Prioritised needs and strategic actions	Associated timeline for completing the actions	Does this require technical assistance?*(yes/no) If yes, indicate type of assistance needed
To undertake a capacity gap analysis of Management of EPI program at different levels (subject to tool being available by end of 2016)	June 2017	Yes under SFA of LMC
Strengthen LMC	2017	Yes, funds to be confirmed by Gavi

²⁶ Please note that Sudan’s request for IPV support was approved, but due to worldwide IPV supply constrains the relevant decision letter will be sent at a later date, once supply issues have been resolved.

Prioritised needs and strategic actions	Associated timeline for completing the actions	Does this require technical assistance?*(yes/no) If yes, indicate type of assistance needed
Finalization of development of HR retention policy	June 2017	Yes, covered under HSS
Enhance capacity and involvement of CSO's in immunization program with a focus on underserved areas.	Dec 2017	Yes, covered under HSS
Strengthen capacity in vaccine management (wastage and temperature monitoring study)	June 2017	Yes, covered by PEF and PBF
Strengthen VPD surveillance system	Dec 2017	Yes, travel cost covered by PEF
Support scale up of the surveillance reporting sites for integrated VPD surveillance with increased alertness to polio.	Dec 2017	Subject to funds not being available from other sources opportunities though PBF will be explored.
Provide support to ensure financial sustainability of service delivery	January – December 2017	Yes, TA is needed in the form of providing hands-on support and technical guidance for the implementation of the Health Financing Strategy by The World Bank to complement WHO/EU support
Support participation in the One JANS (Joint Assessment of the National Health Sector Strategic Plan and cMYP 2017 – 2021)	December 2016 – January 2017	NO
Resource estimation to approach universal coverage by essential health benefit package	December 2016 – June 2017	Yes, World Bank is to continue providing technical assistance to design and conduct the study
Enhance and strengthen the financial management capacity by hiring two finance staff	January – December 2017	No
Strengthening of C4D strategy and social mobilisation of paid volunteers who follow up on defaulters	January – December 2017	Yes PBF
Review and finalise external audit report	September 2016	No
Conduct barrier to immunization study in the different low coverage localities.	October 2016 – December 2016	Yes, Cost available in Country under PEF
Develop and finalize comprehensive context-specific state communication strategies and initiate implementation of communication plans	October 2016 – August 2017	Yes, Cost available under PEF
Support the strengthening of the unified supply system	October 2016 – December 2016	Yes, Cost available under PEF
TA to support supply and cold chain system	October 2016 – August 2017	Yes, Cost available under PEF
Complete yellow fever mass campaigns depending on supply availability	2017	Funding to be confirmed through the vaccine renewal processes

